Navigation Links
IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial

- Results show UVIDEM was well-tolerated with signs of durable disease control in advanced melanoma patients -

IRVINE, Calif., June 05, 2007 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. today presented preliminary results from a Phase II UVIDEM (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). The results showed that UVIDEM was well tolerated with evidence of efficacy and induction of immune response in patients with progressive metastatic melanoma.

The data were presented by Merrick I. Ross, M.D., Professor of Surgery, Chief, Melanoma Section, Department of Surgical Oncology at The University of Texas M. D. Anderson Cancer Center in Houston as an oral presentation titled "Clinical and immunological responses in patients with malignant melanoma treated with a dendritic cell-based vaccine. Preliminary report from a multi- institutional phase II clinical trial" (# 3004) at the 2007 American Society of Clinical Oncology (ASCO) 43rd annual meeting in Chicago.

"We are in great need of new drugs to treat our patients with metastatic melanoma" said Dr. Ross. "The preliminary analysis of the phase II clinical trial with IDM Pharma's cancer vaccine, UVIDEM, suggests that several patients with advanced melanoma attained durable control of their disease after a treatment stimulating their own immune system cells. Additionally, the side effects experienced by our patients were minimal," he added.

Study design and findings

DC-MEL-202 is a single arm, two-stage Phase II trial designed to evaluate clinical and immunological activities and the safety of a multivalent dendritic cell-based vaccine in patients with in-transit or low volume metastatic melanoma. Thirty-three patients were treated in the study and the results to date are as follows:

    --  Clinical response (RECIST): out of 30 patients evaluable for efficacy,

        9 (30%) showed evidence of clinical benefit (1 complete re
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... Feb. 23, 2011 Reportlinker.com announces that a ... catalogue: Global Medical Ultrasound ... This report analyzes the worldwide ... by the following end use segments: Radiology, Cardiology, ...
... Calif., Feb. 23, 2011 Omnicell, Inc ., ... medication management systems to healthcare facilities, today announced the ... healthcare executives were polled to identify trends in requirements ... decisions. The survey found that the majority of hospitals ...
Cached Medicine Technology:Reportlinker Adds Global Medical Ultrasound Equipment Industry 275 Percent of Hospital IT Leaders View Interoperability Between Vendor Systems as Critical to Operational Effectiveness in Healthcare Settings 2
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Losing Weight Your ... industry is staring you in the face, it certainly can ... not do your body an extra favor by doing it ... tempting crash diets. Instead, listen to your body, exercise regularly, ... Exercise is essential to losing weight; you need to exercise ...
(Date:10/22/2014)... Richard Carlson, Managing Partner of Blue ... over 25 years experience. Mr. Carlson is a ... related to EDI, B2B Commerce, RFID and Internet/Intranet technology. ... Board member for Pharmaceutical Commerce Magazine and a Gerson ... is a management and technology consulting firm focused solely ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... By Maureen Salamon ... -- A crucial part of conventional in vitro fertilization (IVF) ... can instead take place in a device inside the vagina, ... Colombia contend that the device, called an INVOcell, might sharply ... could also make the technology more accessible to those who ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... SEGUNDO, Calif., Nov. 3 DaVita Inc. (NYSE:,DVA) ... 30, 2008. Net,income for the three and nine ... $275.8 million, or $0.89 per share and $2.59 ... Net income for the three months ended September ...
... say a home safety review could cut odds of fractures ... News) -- Former first lady Nancy Reagan and Democratic ... hip injuries. And on Friday, author Studs Terkel died, following ... decline. , Such news, experts say, should be a reminder ...
... be changed , , SATURDAY, Nov. 1 (HealthDay News) -- ... according to a UCLA study of almost 1,500 patients ... and need to be treated accordingly. , The UCLA ... approach needs to be changed. , "We have shown ...
... American Academy of Otolaryngology Head and Neck ... guideline to help healthcare practitioners identify and treat ... of the most common underlying conditions that cause ... BPPV, the most common vestibular (inner ear) disorder ...
... Entrees Provide Easy, Delicious, Relief During ... Stressful Election Times, EDISON, N.J., Oct. ... isn,t much time to think about what to eat,let alone cook an ... stress with their delicious and easy gourmet,Indian cuisine that can be made ...
... wardrobe could have been spent on ... healthcare, housing, ... the http://www.DressLikePalin.com website this week, scores offering,their views on ... National Committee famously spent on the wardrobe for Gov. Sarah,Palin., ...
Cached Medicine News:Health News:DaVita 3rd Quarter 2008 Results 2Health News:DaVita 3rd Quarter 2008 Results 3Health News:DaVita 3rd Quarter 2008 Results 4Health News:DaVita 3rd Quarter 2008 Results 5Health News:DaVita 3rd Quarter 2008 Results 6Health News:DaVita 3rd Quarter 2008 Results 7Health News:DaVita 3rd Quarter 2008 Results 8Health News:DaVita 3rd Quarter 2008 Results 9Health News:DaVita 3rd Quarter 2008 Results 10Health News:DaVita 3rd Quarter 2008 Results 11Health News:DaVita 3rd Quarter 2008 Results 12Health News:DaVita 3rd Quarter 2008 Results 13Health News:DaVita 3rd Quarter 2008 Results 14Health News:DaVita 3rd Quarter 2008 Results 15Health News:DaVita 3rd Quarter 2008 Results 16Health News:DaVita 3rd Quarter 2008 Results 17Health News:Falls Are Leading Cause of Injury to Seniors 2Health News:Tailored Treatment Boosts Kidney Cancer Survival 2Health News:ENT doctors release national guideline on treatment for common cause of dizziness 2Health News:ENT doctors release national guideline on treatment for common cause of dizziness 3Health News:Easy Ethnic Election 2Health News:Tens of Thousands View DressLikePalin Web Site 2Health News:Tens of Thousands View DressLikePalin Web Site 3
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
10 (mm) smooth platform; Serrated handle in stainless steel....
... first digital solution designed specifically for cardiologists ... outside cardiology. From the server core to ... combined expertise in both cine film and ... work the way they want, wherever they ...
... Medison SonoAce 9900 is ... based ultrasound system, with ... is DICOM compatible, designed ... general imaging, obstetrics, gynecology, ...
Medicine Products: